Press Releases
At Pulmatrix, we are committed to communicating clear and consistent information. Here we feature current and historic content concerning our science, our pipeline, and our corporate initiatives and achievements. Please check in often for the most recent press releases and information.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 9, 2023
Patient enrollment for the Phase 2b study of PUR1900 is ongoing with four additional sites added during Q3, totaling seventeen active sites to date in four countries; topline data anticipated in...
-
Sep 19, 2023
Pulmatrix received a study may proceed letter for a Phase 2 Study to Evaluate PUR3100, an orally inhaled dry powder formulation of dihydroergotamine ("DHE") in the treatment of acute migraine...
-
Aug 23, 2023
Results demonstrate a low likelihood of clinically meaningful drug-drug interactions when PUR1900 is administered with medications contraindicated with oral itraconazole Pulmatrix is currently...
-
Aug 10, 2023
Subject enrollment for the Phase 2b study of PUR1900 is ongoing with five additional sites added during Q2, totaling thirteen active sites to date in four countries, and topline data anticipated...
-
Jul 11, 2023
Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous...
-
Jun 15, 2023
Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its...
-
May 24, 2023
Presentation will showcase Company's patented iSPERSE™ technology and positive topline results from Phase 1 study of PUR3100 for acute migraine LEXINGTON, Mass., May 24, 2023 /PRNewswire/ --...
-
May 12, 2023
Patient dosing initiated for Phase 2b study of PUR1900 for ABPA Phase 1 study of PUR3100 for migraine achieves positive topline results $30.8 million in cash and cash equivalents at the end of Q1...
-
May 2, 2023
Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its...
-
Mar 30, 2023
PUR1900 Phase 2b study dosed first patients in Q1 2023 PUR3100 Phase 1 study achieves positive topline results as announced in Q1 2023 $35.6 million in cash and cash equivalents at the end of 2022...
-
Feb 6, 2023
Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE™ technology, today...
-
Jan 25, 2023
Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE™ technology, today...
-
Jan 23, 2023
Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE™ technology, today...
-
Jan 4, 2023
PUR3100 was safe and all doses had fewer GI side effects compared to IV DHE PUR3100 demonstrated a five-minute Tmax and Cmax within the targeted therapeutic range for all three doses tested...
-
Nov 10, 2022
PUR1900 (Pulmazole) on track for Phase 2 study start in Q1 2023 PUR3100 Phase 1 study top line data anticipated in early Q1 2023 $40.7 million in cash and cash equivalents at end of Q3 2022...
-
Sep 26, 2022
Company is evaluating its iSPERSE™ orally inhaled dry powder formulation of dihydroergotamine (DHE) for treatment of acute migraine and expects pharmacokinetic data from the Phase 1 study in Q4 2022
-
Aug 8, 2022
Pulmazole is on track for Phase 2b study start in Q1 2023 PUR3100 Phase 1 study is underway with data anticipated in Q4 2022 Ends Q2 with $42.9 million in cash and cash equivalents LEXINGTON,...
-
Jul 12, 2022New inhaled formulation of dihydroergotamine (DHE) intended for acute migraine therapy begins clinical development with Phase 1 study
Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE™ technology, today...
-
May 12, 2022
Ends Q1 with $47.5 million in cash and cash equivalents; Extends cash runway into Q2 2024 LEXINGTON, Mass., May 12, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage...
-
Mar 29, 2022
Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented...
-
Mar 21, 2022
Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented...
-
Mar 17, 2022
Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented...
-
Mar 1, 2022
Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented...
-
Feb 24, 2022
Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM) a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary...
-
Feb 1, 2022
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented...
-
Dec 17, 2021
Pulmatrix, Inc. (Nasdaq: PULM) ("Pulmatrix" or the "Company"), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary...
-
Dec 15, 2021
Pulmatrix, Inc. (Nasdaq: PULM) ("Pulmatrix" or the "Company"), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary...
-
Nov 10, 2021Pulmazole contract dispute with Cipla resolved, expect to initiate Ph2b study in Q1 2023 for treatment of Allergic Bronchopulmonary Aspergillosis (ABPA)
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented...
-
Nov 9, 2021
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented...
-
Aug 10, 2021PUR1800 Phase 1b study is fully enrolled with data anticipated in Q1 2022
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented...
-
Jul 27, 2021
Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented...
-
May 11, 2021PUR1800 Phase 1b data anticipated in Q4 2021
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented...
-
Apr 15, 2021
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented...
-
Apr 12, 2021Corrected: Pulmatrix to Regain Full Rights to PUR1800 and Narrow Spectrum Kinase Inhibitor PortfolioTermination of License, Development and Commercialization Agreement with the Lung Cancer Initiative at Johnson & Johnson will Return Portfolio to Pulmatrix
Pulmatrix, Inc. (NASDAQ: PULM), is re-issuing this press release solely to correct inadvertent typographical errors under the heading "Updated PUR1800 Program Guidance" which incorrectly noted...
-
Mar 23, 2021Initiated PUR1800 Phase 1b study with data anticipated in Q4 2021
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented...
-
Mar 4, 2021PUR1800 Phase 1b study dosing is underway with data anticipated in Q4 2021
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented...
-
Feb 16, 2021
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented...
-
Feb 11, 2021
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented...
-
Nov 12, 2020Focused pipeline with multiple potential clinical and regulatory milestones in 2021
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented...
-
Oct 21, 2020Series of Scientific Publications Demonstrate up to 99% Reduction of Airborne Respiratory Droplets Including Those not Captured by Surgical Masks
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary and non-pulmonary disease using its patented iSPERSE™...
-
Sep 30, 2020FEND Administration Lowered Exhaled Particles in Subjects Including Healthy Subjects and a COVID-19 Patient
LEXINGTON, Mass., Sept. 30, 2020 /PRNewswire/ – Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary and...
-
Sep 29, 2020
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented...
-
Sep 22, 2020
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented...
-
Aug 7, 2020Strategic Partner Sensory Cloud Advancing Toward Commercial Launch of FEND in Fall 2020 as OTC Nasal Hygiene Product for COVID-19
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented...
-
Jul 8, 2020Pulmatrix's Partner Sensory Cloud to Conduct Worldwide Marketing Distribution
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to serious pulmonary and non-pulmonary disease using its patented iSPERSE™...
-
Jun 26, 2020
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to serious pulmonary and non-pulmonary disease using its patented iSPERSE™...
-
May 27, 2020
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented...
-
May 14, 2020
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented...
-
Apr 16, 2020
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented...
-
Apr 16, 2020
Pulmatrix, Inc. (NASDAQ: PULM) a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases today announced it has entered into a...
-
Mar 26, 2020Initiated Phase 2 study evaluating Pulmazole for the treatment of ABPA
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented...
-
Jan 30, 2020
Pulmatrix, Inc. (NASDAQ: PULM) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PUR1900 ("Pulmazole"), the Company's inhaled itraconazole...
-
Jan 16, 2020
Pulmatrix, Inc. (NASDAQ: PULM) announced today that it received a letter from the listing qualifications department staff of The Nasdaq Stock Market LLC, stating that the Company has regained...
Jan 6, 2020Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases today announced that it has entered into a...
- Jan 2, 2020
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has entered into a...
- Nov 4, 2019
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases today announced the appointment of Rick...
- Nov 1, 2019
Pulmatrix, Inc. (NASDAQ: PULM) today reports its third quarter results. Q3 2019 Highlights Pulmatrix achieved clinical and business milestones which reflect the Company's progress. These...
- Sep 18, 2019Phase 2 clinical trial initiated and enrollment progressing across 24 sites
Pulmatrix, Inc. (NASDAQ: PULM) today announced that the first patient has been dosed in the Phase 2 trial evaluating Pulmazole, an inhaled iSPERSE formulation of the antifungal itraconazole in...
- Aug 19, 2019US Patent (Pat. No. 10376465) protects iSPERSE formulations for Pulmazole
Pulmatrix, Inc. (NASDAQ: PULM) has received a grant from the United States Patent and Trademark Office for US Pat. No. 10376465. Granted claims cover iSPERSE formulations of the company's lead...
- Aug 5, 2019
Pulmatrix, Inc. (NASDAQ: PULM) today reports its second quarter results. Q2 2019 Highlights Pulmatrix achieved several clinical and business milestones which reflect the Company's progress. These...
- Jul 9, 2019
Pulmatrix, Inc. (NASDAQ: PULM) announces today that three sites in the United States have been activated for the Phase 2 clinical investigation for Pulmazole (PUR1900) – an inhaled iSPERSETM...
- May 16, 2019
Pulmatrix, Inc. (NASDAQ: PULM) announces today that Dr. Robert Clarke has stepped down as Chief Executive Officer. Ted Raad will immediately transition from his current role as Chief Business...
- May 15, 2019
Pulmatrix, Inc. (NASDAQ: PULM) today reports its first quarter results. "We reached a major milestone in the first quarter with the FDA providing approval to begin our planned Pulmazole Phase 2...
- Apr 15, 2019- Transaction marks Cipla's entry into specialty respiratory segment, building on inroads made into the specialty business in the recent past
Pulmatrix, Inc. (NASDAQ: PULM; hereafter referred to as "Pulmatrix"), a clinical stage biopharmaceutical company focused on developing novel inhaled therapeutics to serve unmet needs in...
- Apr 8, 2019Underwriter Exercises In Full Option to Purchase Additional Securities
Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (NASDAQ: PULM) today announced the closing of its previously announced underwritten public offering of an aggregate of 1,719,554...
- Apr 3, 2019
Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (NASDAQ: PULM) today announced the pricing of its previously announced underwritten public offering of an aggregate of 10,666,666...
- Apr 1, 2019The Binding Term Sheet Executed on April 1, 2019 Lays Groundwork for Entry into a Definitive Agreement During the 2nd Quarter of 2019
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company focused on developing novel inhaled therapeutics to serve unmet needs in respiratory disease, announced today its entry...
- Mar 14, 2019
Pulmatrix, Inc. (NASDAQ: PULM) announced today that members of its management team will present/participate in investor meetings at the following upcoming conferences: Oppenheimer's 29th Annual...
- Mar 12, 2019
Pulmatrix, Inc. (NASDAQ: PULM) announced today that it received a letter from the listing qualifications department staff of The NASDAQ Stock Market LLC, stating that the Company has regained...
- Feb 19, 2019
Pulmatrix, Inc. (NASDAQ: PULM) today announces 2018 financial results, reviews the Company's recent progress, and provides an outlook for its pulmonary disease development pipeline. "The funds...
- Feb 12, 2019PUR1800 (1 US Patent) and PUR5700 (2 US Patents and 2 EU Patents) Intellectual Property Portfolio Expands Significantly
Pulmatrix, Inc. (NASDAQ: PULM) has been awarded five new patents that expand the intellectual property protection for Pulmatrix's PUR1800 and PUR5700 programs. These patents expand the...
- Feb 8, 2019
Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (NASDAQ: PULM) today announced that it has entered into a securities purchase agreement with certain institutional investors,...
- Feb 7, 2019Pulmatrix notified of FDA's authorization to proceed for a Phase 2 study of Pulmazole (inhaled itraconazole) in asthmatic patients with allergic bronchopulmonary aspergillosis (ABPA)
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company focused on developing novel inhaled therapeutics to serve unmet needs in respiratory disease, announced today that the US...
- Feb 6, 2019Files Withdrawal of Registration Statement with the SEC
Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (NASDAQ: PULM) today announced the termination of its previously planned underwritten public offering, with Oppenheimer & Co.,...
- Feb 5, 2019
Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (NASDAQ: PULM) today announced a 1-for-10 reverse split of its common stock, effective as of 5:00 pm Eastern Time, February 5,...
- Feb 5, 2019
Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (NASDAQ: PULM) today announced the closing and funding of its previously announced underwritten public offering of 5,323,530...
- Jan 31, 2019
Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (NASDAQ: PULM) today announced the closing and funding of its previously announced underwritten public offering of 1,561,177...
- Jan 30, 2019
Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (NASDAQ: PULM) today announced the pricing of an underwritten public offering of 5,323,530 shares of its common stock at a price...
- Jan 30, 2019
LEXINGTON, Mass., Jan. 30, 2019 /PRNewswire/ – Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (NASDAQ: PULM) today announced that it intends to offer and sell, subject to...
- Jan 28, 2019
Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (NASDAQ: PULM) today announced the pricing of an underwritten public offering of 1,561,177 shares of its common stock at a price...
- Jan 28, 2019
Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (NASDAQ: PULM) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common...
- Nov 29, 2018
Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (NASDAQ: PULM) today announced that it has entered into a securities purchase agreement with an institutional investor, providing...
- Nov 21, 2018All objectives from the Phase 1/1b study successfully met, on track to initiate a Phase 2 study in asthmatic patients with allergic bronchopulmonary aspergillosis (ABPA) in 2018
Pulmatrix, Inc. (NASDAQ: PULM) announced the results of the completed first-in-human study of Pulmazole (PUR1900) — an inhaled iSPERSETM formulation of the anti-fungal drug itraconazole for the...
- Nov 15, 2018
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases will present the results of the recently...
- Nov 14, 2018
Pulmatrix, Inc. (NASDAQ: PULM) today reported its third quarter results. "We remain focused on advancing the clinical development of our Pulmazole program," said Robert W. Clarke, Ph.D., chief...
- Sep 17, 2018
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases will present preclinical data on the...
- Aug 28, 2018
Pulmatrix, Inc. (NASDAQ: PULM) will present at the Rodman & Renshaw 20th Annual Global Investment Conference on Wednesday, September 5, 2018 at 10:00 AM EDT in the Lotte New York Palace Hotel in...
- Aug 3, 2018
Pulmatrix, Inc. (NASDAQ: PULM) today reports its second quarter results. "We are pleased with the preliminary results of the three-part Phase 1/1b clinical trial of Pulmazole. The data supports...
- Jul 23, 2018Members include experts in both clinical research and management of Allergic Bronchopulmonary Aspergillosis and Asthma
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced today the formation of the...
- Jul 17, 2018Pulmatrix Announces Positive Top-Line Preliminary Results from Part 3 of the 3-Part Phase 1/1b Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE™ Formulation of ItraconazoleSingle dose of Pulmazole safe and well tolerated in subjects with asthma
Pulmatrix, Inc. (NASDAQ: PULM) announced today that all dosing and follow up visits have been completed for Part 3 of the ongoing first-in-human study of Pulmazole (PUR1900) - an inhaled iSPERSETM...
- Jun 25, 2018All doses were well tolerated in normal healthy volunteers in Parts 1 and 2 at up to 35 mg of itraconazole, the maximal dose planned
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced today top-line results for the...
- Jun 13, 2018Data published in the British Journal of Clinical Pharmacology demonstrate that PUR0200 achieves similar improvements in lung function to Spiriva® HandiHaler® at significantly lower doses
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced today the publication of data...
- Jun 7, 2018No Imminent Plan to Effect Reverse Stock Split
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced today that each of the following...
- May 17, 2018Pulmatrix selected to present company profile at the 2018 Respiratory Innovation Summit in San DiegoCompany will also present pre-clinical data on RV1162 (PUR1800) at the affiliated American Thoracic Society 2018 International Conference in San Diego
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases has been selected to present at the 2018...
- May 11, 2018
Pulmatrix, Inc. (NASDAQ: PULM) today reports its first quarter results. "We reached a major milestone for our Pulmazole program in the first quarter with the initiation of dosing in our phase 1/1b...
- Mar 29, 2018
Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (NASDAQ: PULM) today announced the pricing of an underwritten public offering of an aggregate of 23,500,000 units. Each unit is...
- Mar 13, 2018
Pulmatrix, Inc. (NASDAQ: PULM) today announces 2017 financial results, reviews the Company's recent progress, and provides an outlook for its pulmonary disease development pipeline. "The Company...
- Feb 12, 2018Phase 1 data is expected in mid-2018
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced today that the single dose...
- Jan 24, 2018
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced today that it will present new...
- Jan 22, 2018Screening of subjects for this first-in-human study has begun and represents an important milestone in advancing this first in class therapy to the clinic
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced today that it has received...
